This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): AK-120, Famciclovir

Description: Famvir undergoes rapid biotransformation to the active antiviral compound penciclovir, which ahs inhibitory activity against cells infected with herpes simplex virus types 1 (HSV-1) or type 2 (HSV-2) or varicella zoster virus (VZV). In infected cells, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that is converted to penciclovir triphosphate by cellular kinases. Penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and replication are selectively inhibited.

Deal Structure: Novartis and Asahi Kasei
In January 2008, Novartis granted Asahi Kasei the right to distribute Famvir in Japan pursuant to a Restated Distribution Agreement.

Asahi Kasei and Maruho
In April 2008, Asahi Kasei entered into a marketing alliance with Maruho for famciclovir in the Japanese Market.

Partners: Asahi Kasei Corporation Maruho Co., Ltd.

Famvir News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug